Predictors of 5-year mortality in pulmonary Mycobacterium avium-intracellulare complex disease

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 3, 2012, Pages 408-414

  Ito, Yutaka ^a   Hirai, T ^a   Maekawa, K ^a   Fujita, K ^a   Imai, S ^a   Tatsumi, S ^a   Handa, T ^a   Matsumoto, H ^a   Muro, S ^a   Niimi, A ^a   Mishima, M ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Cavitary lesion; Charlson comorbidity index; Ethambutol; Mortality; Mycobacterium avium intracellulare complex

Indexed keywords

CLARITHROMYCIN; ETHAMBUTOL; ISONIAZID; LEVOFLOXACIN; RIFAMPICIN;

AGED; ARTICLE; ATYPICAL MYCOBACTERIOSIS; CHARLSON COMORBIDITY INDEX; CLINICAL ASSESSMENT; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE DISEASE; FEMALE; HUMAN; JAPAN; LABORATORY DIAGNOSIS; LUNG FUNCTION TEST; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SCORING SYSTEM; SPUTUM CULTURE; SPUTUM SMEAR; THORAX RADIOGRAPHY; VISUAL DISORDER;

AGED; ANTI-BACTERIAL AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84857304636     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.11.0148     Document Type: Article

References (18)

1. Griffith D E, Aksamit T, Brown-Elliott B A, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of non-tuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416.
2. Thomson R M, Yew W W. When and how to treat pulmonary non-tuberculous mycobacterial diseases. Respirology 2009; 14: 12-26.
3. Wallace R J Jr, Brown B A, Griffith D E, Girard W M, Murphy D T. Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. Am J Respir Crit Care Med 1996; 153: 1766-1772. (Pubitemid 26187897)
4. Tanaka E, Kimoto T, Tsuyuguchi K, et al. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med 1999; 160: 866-872. (Pubitemid 29442022)
5. Research Committee of the British Thoracic Society. First randomised trial of treatments for pulmonary disease caused by M. avium intracellulare, M. malmoense and M. xenopi in HIV-negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol. Thorax 2001; 56: 167-172.
6. Lam P K, Griffith D E, Aksamit T R, et al. Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006; 173: 1283-1289. (Pubitemid 43848401)
7. Kobashi Y, Matsushima T, Oka M. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Respir Med 2007; 101: 130-138. (Pubitemid 44835234)
8. Jenkins P A, Campbell I A, Banks J, Gelder C M, Prescott R J, Smith A P. Clarithromycin vs. ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy. Thorax 2008; 63: 627-634. (Pubitemid 351969257)
9. Ye J J, Wu T S, Chiang P C, Lee M H. Factors that affect sputum conversion and treatment outcome in patients with Mycobacterium avium-intracellulare complex pulmonary disease. J Microbiol Immunol Infect 2007; 40: 342-348.
10. Yeager H Jr, Raleigh J W. Pulmonary disease due to Mycobacterium intracellulare. Am Rev Respir Dis 1973; 108: 547-552.
11. Rosenzweig D Y. Pulmonary mycobacterial infections due to Mycobacterium intracellulare-avium complex. Clinical features and course in 100 consecutive cases. Chest 1979; 75: 115-119. (Pubitemid 9128100)
12. Ahn C H, Ahn S S, Anderson R A, Murphy D T, Mammo A. A four-drug regimen for initial treatment of cavitary disease caused by Mycobacterium avium complex. Am Rev Respir Dis 1986; 134: 438-441.
13. Research Committee of the British Thoracic Society. Pulmonary disease caused by Mycobacterium avium-intracellulare in HIV-negative patients: five-year follow-up of patients receiving standardised treatment. Int J Tuberc Lung Dis 2002; 6: 628-634.
14. Andréjak C, Lescure F X, Douadi Y, et al. Non-tuberculous mycobacteria pulmonary infection: management and follow-up of 31 infected patients. J Infect 2007; 55: 34-40. (Pubitemid 46888075)
15. Andréjak C, Thomsen V Ø, Johansen I S, et al. Non-tuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors. Am J Respir Crit Care Med 2010; 181: 514-521.
16. Charlson M E, Pompei P, Ales K L, MacKenzie C R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383. (Pubitemid 17055592)
17. Hasegawa N, Nishimura T, Ohtani S, et al. Therapeutic effects of various initial combinations of chemotherapy including clarithromycin against Mycobacterium avium complex pulmonary disease. Chest 2009; 136: 1569-1575.
18. Field S K, Fisher D, Cowie R L. Mycobacterium avium complex pulmonary disease in patients without HIV infection. Chest 2004; 126: 566-581. (Pubitemid 39093445)